Imunon Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
IMNN$0.88+4.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
YEAR ENDED DECEMBER 31, 2023
| Common Stock Outstanding · Additional Paid-in · Treasury Stock · Accum. Other Compr. Income · Accumulated | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Shares | Amount | (Loss) | Deficit | Total | |
| Balance at January 1, 2023 | 7,436,219 | $74,362 | $397,980,023 | 22 | $(85,188) | $26,494 | $(368,667,825) | $29,327,866 |
| Net loss | - | - | - | - | - | - | (19,514,977) | (19,514,977) |
| Sale of equity through equity financing facilities | 1,904,142 | 19,041 | 2,762,397 | - | - | - | - | 2,781,438 |
| Issuance of common stock upon exercise of restricted options | 59,450 | 595 | - | - | - | - | - | 595 |
| Realized and unrealized gains, net, on investment securities | - | - | - | - | - | 34,302 | - | 34,302 |
| Stock-based compensation expense | - | - | 758,418 | - | - | - | - | 758,418 |
| Balance at December 31, 2023 | 9,399,811 | $93,998 | $401,500,838 | 22 | $(85,188) | $60,796 | $(388,182,802) | $13,387,642 |
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
YEAR ENDED DECEMBER 31, 2022
| Series A & B Preferred · Common Stock Outstanding · Additional Paid-in · Treasury Stock · Accum. Other Compr. Income · Accumulated | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount · Capital · Shares · Amount · (Loss) · Deficit · Total | |||||||||||
| Balance at January 1, 2022 | - | $ | - | 5,770,516 | $57,705 | $388,600,979 | 22 | $(85,188) | $(7,974) | $(332,769,591) | $55,795,931 |
| Net loss | - | - | - | - | - | - | - | - | (35,898,234) | (35,898,234) | |
| Effect of reverse stock split | - | - | (27) | - | - | - | - | - | - | - | |
| Issuance of preferred stock upon financing | 100,000 | 28,500,000 | - | - | - | - | - | - | - | 28500,000 | |
| Redemption of preferred stock | (100,000) | (28,500,000) | - | - | - | - | - | - | - | (28,500,000) | |
| Sale of equity through equity financing facilities | - | - | 1,664,349 | 16,644 | 6,706,010 | - | - | - | - | 6,722,654 | |
| Issuance of common stock for restricted options | - | - | 1,381 | 13 | - | - | - | - | - | 13 | |
| Realized and unrealized gains, net, on investment securities | - | - | - | - | - | - | - | 34,468 | - | 34,468 | |
| Stock-based compensation expense | - | - | - | - | 2,673,034 | - | - | - | - | 2,673,034 | |
| Balance at December 31, 2022 | - | $ | - | 7,436,219 | $74,362 | $397,980,023 | 22 | (85,188) | $26,494 | $(368,667,825) | $29,327,866 |
See accompanying notes to the consolidated financial $$statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.